Reduction in grey matter atrophy in patients with relapsing multiple sclerosis following treatment with cladribine tablets

BACKGROUND AND PURPOSE: Measures of atrophy in the whole brain can be used to reliably assess treatment effect in clinical trials of patients with multiple sclerosis (MS). Trials assessing the effect of treatment on grey matter (GM) and white matter (WM) atrophy are very informative, but hindered by...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortese, Rosa, Battaglini, Marco, Sormani, Maria Pia, Luchetti, Ludovico, Gentile, Giordano, Inderyas, Maira, Alexandri, Nektaria, De Stefano, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Multiple Sclerosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091690/
https://www.ncbi.nlm.nih.gov/pubmed/36168741
http://dx.doi.org/10.1111/ene.15579

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091690/
https://www.ncbi.nlm.nih.gov/pubmed/36168741
http://dx.doi.org/10.1111/ene.15579

Ejemplares similares